Key TakeawaysEli Lilly shares climbed over 4% during early Monday session following weekend disclosure of promising clinical trial results.The company’s investigational obesity medication retatrutide demonstrated a 60.6% reduction in sleep apnea severity and up to 73.1% decrease in knee pain during Phase 3 studies.Foundayo, Lilly’s oral treatment, produced weight reduction outcomes in women throughout all menopause phases, supported by findings from 1,500 study subjects.Novo Nordisk announced Wegovy surpassed 3 million prescriptions since January rollout — yet shares dropped 3% in early European markets.Over the last twelve months, Eli Lilly shares have gained 47% while Novo Nordisk has declined over 40%.Eli Lilly dominated the weekend news cycle with pharmaceutical updates. The pharmaceutical giant released a series of encouraging clinical trial findings throughout Saturday and Sunday, prompting an immediate market reaction Monday morning — LLY shares surged more than 4% before the opening bell, securing its position as the S&P 500’s second-strongest performer trailing only Micron.Eli Lilly and Company, LLYThe spotlight focused primarily on retatrutide, Lilly’s investigational next-wave obesity treatment. Phase 3 clinical trial data unveiled at the American Diabetes Association gathering in New Orleans demonstrated that the once-weekly injection achieved a 60.6% reduction in moderate-to-severe obstructive sleep apnea severity among obese adults.The identical clinical study revealed retatrutide delivered up to 73.1% reduction in knee osteoarthritis discomfort.These findings complement previously disclosed data where patients living with obesity achieved 28% body weight reduction using the medication, and adults managing type 2 diabetes experienced significant blood glucose improvements.Retatrutide represents Lilly’s “triple G” therapeutic approach — it activates GLP-1, GIP, and glucagon receptors simultaneously, advancing beyond current dual-mechanism medications like Zepbound, which already holds approval for sleep apnea treatment.Among the studies, 2% of diabetic patients receiving the minimum dosage experienced major adverse cardiovascular events. Lilly emphasized these incidents weren’t definitively attributed to the medication. Complete findings appeared in the Lancet on Saturday.Foundayo Broadens Treatment ScopeThe weekend wasn’t finished yet. Sunday brought additional updates when Lilly unveiled analysis demonstrating its oral medication Foundayo produced weight loss across women at all menopause stages. The data emerged from 1,500 female participants enrolled in the company’s ATTAIN-1 and ATTAIN-2 Phase 3 clinical studies.This represents a substantial broadening of the medication’s addressable population, encompassing pre-menopausal, perimenopausal, and post-menopausal women.Novo’s Positive Update Met With Market IndifferenceNovo Nordisk delivered favorable news Monday as well. The Copenhagen-based pharmaceutical company announced its oral Wegovy obesity treatment has surpassed 3 million prescriptions since its pill formulation launched in early January — representing one new prescription approximately every five seconds.Novo characterized it as among the most successful U.S. pharmaceutical product introductions on record.Yet investors remained unimpressed. Novo shares declined 3% during early European trading hours, with American depositary receipts indicating a 1.8% drop ahead of U.S. market open. Denmark’s stock exchange was shuttered Friday, meaning Monday’s movement partly reflected catch-up trading.Novo’s equity has endured a challenging period, tumbling more than 40% throughout the past year. Lilly, conversely, has advanced 47% during the identical timeframe.LLY traded approximately 4% higher Monday morning as the newest data wave continued strengthening its competitive standing in the obesity treatment landscape.The post Eli Lilly (LLY) Stock Surges 4% Following Breakthrough Sleep Apnea Trial Results appeared first on Blockonomi.